Necrostatin-1 is widely used in research to study cell death mechanisms, particularly necroptosis, a form of programmed cell death. It acts as an inhibitor of RIPK1 (receptor-interacting protein kinase 1), a key player in the necroptosis pathway. Researchers utilize Necrostatin-1 to explore its protective effects in various disease models, including ischemic injuries, neurodegenerative disorders, and inflammatory conditions. By blocking necroptosis, it helps in understanding the role of this cell death pathway in tissue damage and disease progression. Additionally, it serves as a tool to differentiate necroptosis from other forms of cell death, such as apoptosis, in experimental studies. Its application extends to potential therapeutic investigations, where it is tested for its ability to mitigate cell death and improve outcomes in conditions like stroke, heart attack, and organ transplantation.